ICU Medical (NASDAQ:ICUI) Hits New 52-Week High at $181.16

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $181.16 and last traded at $181.16, with a volume of 12675 shares traded. The stock had previously closed at $179.00.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ICUI. Raymond James upped their target price on ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a report on Thursday. StockNews.com upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Thursday. KeyCorp boosted their price target on shares of ICU Medical from $136.00 to $147.00 and gave the company an "overweight" rating in a report on Thursday, August 8th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $149.00.

ICU Medical Stock Up 0.3 %

The business has a fifty day moving average price of $145.63 and a two-hundred day moving average price of $119.57. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. The company has a market cap of $4.37 billion, a price-to-earnings ratio of -73.27 and a beta of 0.65.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.56. The firm had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The company's revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.58 EPS. On average, equities analysts predict that ICU Medical, Inc. will post 3.76 earnings per share for the current year.

Insider Buying and Selling at ICU Medical

In other news, VP Virginia Ruth Sanzone sold 2,050 shares of ICU Medical stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the sale, the vice president now directly owns 4,482 shares in the company, valued at approximately $645,901.02. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the business's stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the sale, the vice president now directly owns 4,482 shares of the company's stock, valued at $645,901.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the firm's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,096,771.78. The disclosure for this sale can be found here. Insiders have sold 28,552 shares of company stock worth $4,537,802 over the last 90 days. 6.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in ICU Medical by 14.8% during the fourth quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier's stock worth $243,438,000 after purchasing an additional 315,103 shares during the period. Norges Bank acquired a new position in shares of ICU Medical during the 4th quarter worth about $20,669,000. The Manufacturers Life Insurance Company boosted its stake in ICU Medical by 539.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 177,009 shares of the medical instruments supplier's stock valued at $17,655,000 after purchasing an additional 149,313 shares during the period. Silvercrest Asset Management Group LLC grew its holdings in ICU Medical by 109.4% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier's stock valued at $29,882,000 after buying an additional 145,485 shares during the last quarter. Finally, Mesirow Institutional Investment Management Inc. bought a new position in ICU Medical in the 1st quarter worth approximately $15,425,000. Institutional investors and hedge funds own 96.10% of the company's stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.